AllianceBernstein’s Mineralys Therapeutics MLYS Stock Holding History

AllianceBernstein’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.9M	Buy	1,067,541 +91,580	+9%	+$2.51M	0.01%	795
2026 Q1	$35.4M	Buy	975,961 +53,445	+6%	+$1.57M	0.01%	709
2025 Q4	$33.5M	Buy	922,516 +40,101	+5%	+$1.61M	0.01%	745
2025 Q3	$33.5M	Buy	882,415 +855,348	+3,160%	+$18.5M	0.01%	741
2025 Q2	$366K	Buy	27,067 +4,070	+18%	+$59K	﹤0.01%	2821
2025 Q1	$365K	Sell	22,997 -27	-0.1%	-$311	﹤0.01%	2680
2024 Q4	$283K	Buy	23,024 +64	+0.3%	+$837	﹤0.01%	2905
2024 Q3	$278K	Hold	22,960	–	–	﹤0.01%	2948
2024 Q2	$269K	Buy	22,960 +7,100	+45%	+$89.4K	﹤0.01%	2955
2024 Q1	$205K	Hold	15,860	–	–	﹤0.01%	2923
2023 Q4	$136K	Hold	15,860	–	–	﹤0.01%	3028
2023 Q3	$151K	Buy	15,860 +4,780	+43%	+$62.3K	﹤0.01%	3014
2023 Q2	$189K	Buy	+11,080	New	+$166K	﹤0.01%	2996

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AllianceBernstein's MLYS Position: Q2 2026 in Review

AllianceBernstein increased its Mineralys Therapeutics (MLYS) stake by 9.4% in Q2 2026, buying an estimated $2.51M and bringing the position to 1,067,541 shares worth $28.9M. The position accounts for 0.01% of the portfolio, ranked #795.

AllianceBernstein first reported a position in MLYS in Q2 2023 and has held it in 13 quarters since. The position peaked at $35.4M in Q1 2026. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

AllianceBernstein held 1,067,541 shares of Mineralys Therapeutics worth $28.9M as of Q2 2026.
AllianceBernstein bought 91,580 Mineralys Therapeutics shares in Q2 2026, an estimated $2.51M.
Mineralys Therapeutics made up 0.01% of AllianceBernstein's portfolio in Q2 2026, its #795 holding.
AllianceBernstein first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 13 quarters since.
AllianceBernstein's Mineralys Therapeutics position peaked at $35.4M in Q1 2026.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.